#SFHS2536832ADecree of 31 March 2026 on the delisting of pharmaceutical specialties from the list of medicines approved for public authorities under Article L. 5123-2 of the Public Health Code
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This French decree removes the antifungal medicine MYCAMINE 50 mg (micafungine) powder for perfusion from the official list of pharmaceuticals approved for use by public authorities and various public services. The product, presented in glass vials (CIP code 34009 495 007 7), manufactured by Laboratoires ABACUS MEDICINE, will be delisted exactly four days after the decree is published in the Journal Officiel. The removal is made pursuant to Article L. 5123-2 of the French Public Health Code. Once delisted, public hospitals, prisons, armed forces medical services and other public entities will no longer be able to purchase or use this specific presentation under the public procurement and reimbursement framework associated with the approved list.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- MYCAMINE 50 mg (micafungine) powder for perfusion (CIP 34009 495 007 7) is removed from the approved public authorities medicines list
- Delisting takes effect exactly 4 days after publication in the Journal officiel de la République française
- Applies to glass vial presentation (B/1) manufactured by Laboratoires ABACUS MEDICINE
+ 2 more changes with Pro
Obligations
What this law requires
Remove MYCAMINE 50 mg (micafungine) powder for perfusion, CIP code 34009 495 007 7, manufactured by Laboratoires ABACUS MEDICINE from the approved medicines list for public authorities
Cease purchasing and procurement of MYCAMINE 50 mg (micafungine) powder for perfusion, CIP code 34009 495 007 7 under the public procurement framework
Implement the delisting effective date of 4 days following publication of this decree in the Journal Officiel de la République française
Cease reimbursement of MYCAMINE 50 mg (micafungine) powder for perfusion under the public reimbursement framework for the specified CIP code presentation
Publish this decree in the Journal Officiel de la République française